What Happened?
, -based SeLux Diagnostics Appointed Michele Healy as Chief Financial Officer
About the Company
SeLux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic.
About the Person
Michele Healy is Chief Financial Officer at SeLux Diagnostics. Previously, Michele held various senior HR leadership roles in the industry.
Info Source
News
Short Profile